Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-wg55d Total loading time: 0 Render date: 2024-04-30T22:59:04.478Z Has data issue: false hasContentIssue false

Chapter 23 - Neurotransmitter Disorders: Disorders of GABA Metabolism and Movement Disorders

from Section II - A Metabolism-Based Approach to Movement Disorders and Inherited Metabolic Disorders

Published online by Cambridge University Press:  24 September 2020

By
Phillip L. Pearl ,
Melissa DiBacco ,
K. Michael Gibson  and
Jean-Baptiste Roullet
Edited by
Darius Ebrahimi-Fakhari  and
Phillip L. Pearl
Darius Ebrahimi-Fakhari
Affiliation:
Harvard Medical School
Phillip L. Pearl
Affiliation:
Harvard Medical School
Get access

Summary

Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain. The primary precursor of GABA is glutamate, the major excitatory neurotransmitter in the brain. Glutamate is converted into GABA via glutamate decarboxylase (GAD). GABA-transaminase (GABA-T) metabolizes GABA to succinic semialdehyde, which is rapidly metabolized to succinic acid by succinic semialdehyde dehydrogenase (SSADH) and then enters the tricarboxylic acid (TCA) cycle (Figure 23.1).

Type
Chapter
Information
Movement Disorders and Inherited Metabolic Disorders
Recognition, Understanding, Improving Outcomes
 , pp. 296 - 306
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gibson, KM, Sweetman, L, Nyhan, WL, et al. Succinic semialdehyde dehydrogenase deficiency: An inborn error of gamma-aminobutyric acid metabolism. Clin Chim Acta. 1983;133(1):33–42.CrossRefGoogle ScholarPubMed
Attri, SV, Singhi, P, Wiwattanadittakul, N, et al. Incidence and geographic distribution of succinic semialdehyde dehydrogenase (SSADH) deficiency. JIMD Rep. 2017;34:111–5.Google Scholar
Pearl, PL, Parviz, M, Vogel, K, et al. Inherited disorders of gamma-aminobutyric acid metabolism and advances in ALDH5A1 mutation identification. Dev Med Child Neurol. 2015;57(7):611–7.Google Scholar
Gibson, KM, Gupta, M, Pearl, PL, et al. Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria). Biol Psychiatry. 2003;54(7):763–8.CrossRefGoogle ScholarPubMed
Akaboshi, S, Hogema, BM, Novelletto, A, et al. Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Hum Mutat. 2003;22(6):442–50.Google Scholar
Jansen, EE, Vogel, KR, Salomons, GS, et al. Correlation of blood biomarkers with age informs pathomechanisms in succinic semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. J Inherit Metab Dis. 2016;39(6):795–800.CrossRefGoogle ScholarPubMed
Johansen, SS, Wang, X, Sejer Pedersen, D, et al. Gamma-hydroxybutyrate (GHB) content in hair samples correlates negatively with age in succinic semialdehyde dehydrogenase deficiency. JIMD Rep. 2017;36:93–8.Google Scholar
Pearl, PL, Novotny, EJ, Acosta, MT, Jakobs, C, Gibson, KM. Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol. 2003;54 Suppl 6:S73–80.CrossRefGoogle ScholarPubMed
Pearl, PL, Gibson, KM, Acosta, MT, et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology. 2003;60(9):1413–7.CrossRefGoogle ScholarPubMed
Pearl, PL, Capp, PK, Novotny, EJ, Gibson, KM. Inherited disorders of neurotransmitters in children and adults. Clin Biochem. 2005;38(12):1051–8.Google Scholar
Pearl, PL, Shamim, S, Theodore, WH, et al. Polysomnographic abnormalities in succinic semialdehyde dehydrogenase (SSADH) deficiency. Sleep. 2009;32(12):1645–8.Google Scholar
Scherschlicht, R. Role for GABA in the control of the sleep–wakefulness cycle. In Wauquier, A, Gaillard, J, Monti, JM, Radulovacki, M, editors. Sleep: Neurotransmitters and Neuromodulators. New York, NY: Raven Press; 1985, pp. 237–49.Google Scholar
Lapalme-Remis, S, Lewis, EC, De Meulemeester, C, et al. Natural history of succinic semialdehyde dehydrogenase deficiency through adulthood. Neurology. 2015;85(10):861–5.CrossRefGoogle ScholarPubMed
Pearl, PL, Gibson, KM, Cortez, MA, et al. Succinic semialdehyde dehydrogenase deficiency: Lessons from mice and men. J Inherit Metab Dis. 2009;32(3):343–52.Google Scholar
Jakobs, C, Bojasch, M, Monch, E, et al. Urinary excretion of gamma-hydroxybutyric acid in a patient with neurological abnormalities. The probability of a new inborn error of metabolism. Clin Chim Acta. 1981;111(2–3):169–78.CrossRefGoogle Scholar
Pearl, PL, Acosta, MT, Theodore, WH, et al. Human SSADH deficiency: Phenotype and treatment strategies. In Hoffmann, GF, editor. Diseases of Neurotransmission: From Bench to Bed. Heilbronn: SPS Publications; 2004, pp. 187–98.Google Scholar
Pearl, PL, Acosta, MT, Wallis, DD, et al. Dyskinetic features of succinate semialdehyde dehydrogenase deficiency, a GABA degradative defect. In Fernandez-Alvarez, E, Arzimanoglou, A, Tolosa, E, editors. Paediatric Movement Disorders: Progress in Understanding. Esher: John Libbey Eurotext; 2005, pp. 203–12.Google Scholar
Rahbeeni, Z, Ozand, PT, Rashed, M, et al. 4-Hydroxybutyric aciduria. Brain Dev. 1994;16 Suppl:64–71.CrossRefGoogle ScholarPubMed
Zeiger, WA, Sun, LR, Bosemani, T, Pearl, PL, Stafstrom, CE. Acute infantile encephalopathy as presentation of succinic semialdehyde dehydrogenase deficiency. Pediatr Neurol. 2016;58:113–5.Google Scholar
Leuzzi, V, Di Sabato, ML, Deodato, F, et al. Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency. Neurology. 2007;68(16):1320–1.Google Scholar
Pearl, PL, Vezina, LG, Saneto, RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50(2):184–94.CrossRefGoogle ScholarPubMed
Dill, P, Datta, AN, Weber, P, Schneider, J. Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms? Eur J Paediatr Neurol. 2013;17(3):311–5.Google Scholar
Novotny, EJ, Jr., Fulbright, RK, Pearl, PL, Gibson, KM, Rothman, DL. Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol. 2003;54 Suppl 6:S25–31.Google Scholar
Al-Essa, MA, Bakheet, SM, Patay, ZJ, Powe, JE, Ozand, PT. Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (FDG PET), MRI of the brain and biochemical observations in a patient with 4-hydroxybutyric aciduria: A progressive neurometabolic disease. Brain Dev. 2000;22(2):127–31.Google Scholar
Pearl, PL, Gibson, KM, Quezado, Z, et al. Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency. Neurology. 2009;73(6):423–9.Google Scholar
Shinka, T, Ohfu, M, Hirose, S, Kuhara, T. Effect of valproic acid on the urinary metabolic profile of a patient with succinic semialdehyde dehydrogenase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;792(1):99–106.Google Scholar
Escalera, GI, Ferrer, I, Marina, LC, et al. Succinic semialdehyde dehydrogenase deficiency: Decrease in 4-OH-butyric acid levels with low doses of vigabatrin. An Pediatr (Barc). 2010;72(2):128–32.Google ScholarPubMed
Pearl, PL, Gropman, A. Monitoring gamma-hydroxybutyric acid levels in succinate-semialdehyde dehydrogenase deficiency. Ann Neurol. 2004;55(4):599;author replyCrossRefGoogle ScholarPubMed
Ergezinger, K, Jeschke, R, Frauendienst-Egger, G, et al. Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Ann Neurol. 2003;54(5):686–9.Google Scholar
Krauss, GL, Johnson, MA, Miller, NR. Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings. Neurology. 1998;50(3):614–8.Google Scholar
Spence, SJ, Sankar, R. Visual field defects and other ophthalmological disturbances associated with vigabatrin. Drug Saf. 2001;24(5):385–404.Google Scholar
Vanhatalo, S, Nousiainen, I, Eriksson, K, et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia. 2002;43(7):748–56.CrossRefGoogle ScholarPubMed
Pearl, PL, Poduri, A, Prabhu, SP, et al. White matter spongiosis with vigabatrin therapy for infantile spasms. Epilepsia. 2018;59(4):e40-e4.CrossRefGoogle ScholarPubMed
Gupta, M, Greven, R, Jansen, EE, et al. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). J Pharmacol Exp Ther. 2002;302(1):180–7.Google Scholar
Saronwala, A, Tournay, A, Gargus, JJ. Taurine treatment of succinate semialdehyde dehydrogenase (SSADH) deficiency reverses MRI-documented globus lesions and clinical syndrome (abstract). Proceedings of the 15th Annual Clinical Genetics Meeting. Phoenix, AZ: American College of Medical Genetics; 2008, p. 103.Google Scholar
Pearl, PL, Schreiber, J, Theodore, WH, et al. Taurine trial in succinic semialdehyde dehydrogenase deficiency and elevated CNS GABA. Neurology. 2014;82(11):940–4.Google Scholar
Schreiber, JM, Pearl, PL, Dustin, I, et al. Biomarkers in a taurine trial for succinic semialdehyde dehydrogenase deficiency. JIMD Rep. 2016;30:81–7.Google Scholar
Phase 2 clinical trial of sgs-742 therapy in succinic semialdehyde dehydrogenase deficiency: National Library of Medicine; 2013–2019. Available from: https://clinicaltrials.gov/ct2/show/NCT02019667 (accessed December 2019).Google Scholar
Vogel, KR, Ainslie, GR, Roullet, JB, McConnell, A, Gibson, KM. In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of gamma-hydroxybutyrate (GHB) binding. Toxicol In Vitro. 2017;40:196–202.CrossRefGoogle ScholarPubMed
Vogel, KR, Ainslie, GR, Walters, DC, et al. Succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism: An update on pharmacological and enzyme-replacement therapeutic strategies. J Inherit Metab Dis. 2018;41(4):699–708.Google Scholar
Vogel, KR, Ainslie, GR, McConnell, A, Roullet, JB, Gibson, KM. Toxicologic/transport properties of NCS-382, a gamma-hydroxybutyrate (GHB) receptor ligand, in neuronal and epithelial cells: Therapeutic implications for SSADH deficiency, a GABA metabolic disorder. Toxicol In Vitro. 2018;46:203–12.Google Scholar
Jaeken, J, Casaer, P, de Cock, P, et al. Gamma-aminobutyric acid-transaminase deficiency: A newly recognized inborn error of neurotransmitter metabolism. Neuropediatrics. 1984;15(3):165–9.Google Scholar
Koenig, MK, Hodgeman, R, Riviello, JJ, et al. Phenotype of GABA-transaminase deficiency. Neurology. 2017;88(20):1919–24.CrossRefGoogle ScholarPubMed
Nagappa, M, Bindu, PS, Chiplunkar, S, et al. Hypersomnolence–hyperkinetic movement disorder in a child with compound heterozygous mutation in 4-aminobutyrate aminotransferase (ABAT) gene. Brain Dev. 2017;39(2):161–5.Google Scholar
Koenig, MK, Bonnen, PE. Metabolomics profile in ABAT deficiency pre- and post-treatment. JIMD Rep. 2019;43:13–7.Google Scholar
Tsuji, M, Aida, N, Obata, T, et al. A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy. J Inherit Metab Dis. 2010;33(1):85–90.CrossRefGoogle ScholarPubMed
Besse, A, Wu, P, Bruni, F, et al. The GABA transaminase, ABAT, is essential for mitochondrial nucleoside metabolism. Cell Metab. 2015;21(3):417–27.Google Scholar
Ichikawa, K, Tsuji, M, Tsuyusaki, Y, et al. Serial magnetic resonance imaging and (1)H-magnetic resonance spectroscopy in GABA transaminase deficiency: A case report. JIMD Rep. 2019;43:7–12.Google Scholar
Gibson, KM, Schor, DS, Gupta, M, et al. Focal neurometabolic alterations in mice deficient for succinate semialdehyde dehydrogenase. J Neurochem. 2002;81(1):71–9.CrossRefGoogle ScholarPubMed
Chowdhury, GM, Gupta, M, Gibson, KM, Patel, AB, Behar, KL. Altered cerebral glucose and acetate metabolism in succinic semialdehyde dehydrogenase-deficient mice: Evidence for glial dysfunction and reduced glutamate/glutamine cycling. J Neurochem. 2007;103(5):2077–91.Google Scholar
Knerr, I, Pearl, PL, Bottiglieri, T, et al. Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5A1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology. J Inherit Metab Dis. 2007;30(3):279–94.CrossRefGoogle ScholarPubMed
Acosta, MT, Munasinghe, J, Pearl, PL, et al. Cerebellar atrophy in human and murine succinic semialdehyde dehydrogenase deficiency. J Child Neurol. 2010;25(12):1457–61.Google Scholar
DiBacco, ML, Roullet, JB, Kapur, K, et al. Age-related phenotype and biomarker changes in SSADH deficiency. Ann Clin Transl Neurol. 2018;6(1):114–20.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×